Skip to content
Taxonomy
CMTA Supports the Accelerating Kids’ Access to Care Act (H.R.4758 / S.2372) THE CHARCOT-MARIE-TOOTH ASSOCIATION SUPPORTS THE ACCELERATING KIDS’ ACCESS TO CARE Read More
Mindset Strategies for Kids and Teens with CMT Growing up with a disability presents layers of challenges at Read More
Exploring New Therapeutic Pathways for CMT1B: UPR Activation Researchers at the Ospedale San Raffaele (OSR) Scientific Institute in Read More
Advancing the Understanding of CMT2A and CMT2F: A Call to Beat CMT The Charcot-Marie-Tooth Association (CMTA), through its Strategy To Accelerate Research Read More
Let’s Beat CMT – 2024 CMT Awareness Month #LetsBeatCMT is a social media initiative during CMT Awareness Month Read More
CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news Read More
CMTA Alliance Partner Applied Therapeutics Plans to Submit an NDA for CMT-SORD, a Potential First Approval for the Treatment of any type of CMT The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news Read More
Gene Replacement Therapy in CMT4 Subtypes The Charcot-Marie-Tooth Association (CMTA) has announced a $240K investment in Read More
Nanoparticles for CMT1A, CMT1B, and CMTX1: A New Frontier in Gene Therapy In a groundbreaking three-year joint project between the Charcot-Marie-Tooth Association Read More
Repurposing Drugs for CMT1A: An Encouraging Approach Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form Read More